Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21395928 | 0.91 | HTT (0.55) | MPOSMN1; SMN2HTTSLC6A4S1PR1 | |
| SCHEMBL16540014 | 0.82 | MPO (0.49) | MPOSMN1; SMN2HTTSLC6A4DYRK1A | |
| SCHEMBL5058656 | 0.82 | ALDH1A1 (0.45) | MPOSMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL597473 | 0.82 | SMN1; SMN2 (0.66) | MPOSMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL4797310 | 0.79 | DYRK1A (0.47) | MPOSMN1; SMN2HTTSLC6A4DYRK1A | |
| SCHEMBL24961607 | 0.78 | HTT (0.50) | MPOSMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL14631453 | 0.77 | MPO (0.44) | MPOSMN1; SMN2HTTSLC6A4 | |
| SCHEMBL3566049 | 0.77 | ALDH1A1 (0.44) | SMN1; SMN2MEN1KMT2AALDH1A1DYRK1A | |
| SCHEMBL10851385 | 0.76 | CYP1A2 (0.51) | MPOSMN1; SMN2HTTSLC6A4CYP1A2 | |
| SCHEMBL35884 | 0.76 | MEN1 (0.68) | SMN1; SMN2HTTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1852420-B1 | Indole compounds for treating respiratory disorders | ONO PHARMACEUTICAL CO (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-7728023-B2 | Indole compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080188532-A1 | Indole Compound and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-07 | — | — | US | disclosed |
| CN-101128424-A | Indole compound and use thereof | ONO PHARMACEUTICAL CO (JP) | 2008-02-20 | — | — | CN | disclosed |
| EP-1852420-A1 | INDOLE COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188532-A1 | Indole Compound and Use Thereof | CYSLTR1, LTC4S, IDO1 | MPO 679/4885SMN1; SMN2 4777/4885HTT 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.